Kaliziri extract upregulates tyrosinase, TRP-1, TRP-2 and MITF expression in murine B16 melanoma cells

BMC Complementary and Alternative Medicine

Haji Akber Aisa¹  Aiden Eblimit²  Maidina Kabas¹  Ablajan Tulake³  Yong-qiang Liu¹  Adila Tuerxuntayi³ 

[1] State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, Urumqi 830011, China;Human Genome Sequencing Center Department of Molecular and Human Genetics Baylor College of Medicine, Houston, TX 77030, USA;University of the Chinese Academy of Sciences, Beijing 100039, China

关键词: MITF;    TYR;    B16 melanoma cells;    Melanogenesis;    KZE;   

Others  :  1159783
DOI  :  10.1186/1472-6882-14-166

 received in 2013-12-11, accepted in 2014-05-12,  发布年份 2014

【 摘 要 】

Background

Kaliziri extract (KZE) is a traditional Uyghur medicine (TUM), used by traditional hospitals in China as an injection for treatment of vitiligo for more than 30 years. Clinical application has shown that this medicine has obvious therapeutic effects. However, its phytochemical analysis and mechanism have not been examined.

Methods

KZE was extracted from seeds of Kaliziri [Vernonia anthelmintica (L.) Willd.] in ethanol-water (80:20, v/v), its components were identified by LC-MS/MS, and the signaling pathway of melanin synthesis in KZE treated murine B16 melanoma cells was examined by western blotting.

Results

Liquid chromatography-mass spectrometry analysis confirmed that the main components of KZE are flavonoids. KZE increased the tyrosinase activity and melanin content in a dose-dependent manner at concentrations of 5-40 μg/ml, and treatment with 20 μg/ml of KZE enhanced the expression of tyrosinase in B16 cells in a time-dependent manner.

Conclusions

KZE induced melanogenesis by increasing the expression of TYR, TRP-1, TRP-2 and MITF in B16 cells.

【 授权许可】

   
2014 Tuerxuntayi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Upur H, Yusup A, Baudrimont I, Umar A, Berke B, Yimit D, Lapham JC, Creppy EE, Moore N: Inhibition of cell growth and cellular protein, DNA and RNA synthesis in human hepatoma (HepG2) cells by ethanol extract of abnormal Savda Munziq of traditional Uyghur medicine. Evid Based Complement Alternat Med 2011, 2514-2524. doi: 10.1093/ecam/nen062
• [2]Yishakejiang M, Abudureyimu K, Abulake R: China Medical Encyclopedia-Uyghur Medicine Volume. Shanghai, China: Shanghai Science and Technology Press; 2005.
• [3]Chinese Pharmacopoeia Commission: Pharmacopoeia of the People’s Republic of China, Uyghur Medicine Volume. Beijing, China: Chinese Medical Science and Technology Press; 2005:150.
• [4]Guerra L, Dellambra E, Brescia S, Raskovic D: Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab 2010, 11(5):451-467.
• [5]Alikhan A, Felsten LM, Daly M, Petronic-Rosic V: Vitiligo: a comprehensive overview: part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2010, 65:473-491.
• [6]Kakourou T: Vitiligo in children. World J Pediatr 2009, 5(4):265-268.
• [7]Matz H, Tur E: Vitiligo. Curr Probl Dermatol 2007, 35:78-102.
• [8]Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne JP: The Pigmentary System: Physiology and Pathophysiology. New York: Oxford University Press; 1998:1-1025.
• [9]Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, Mendoza-Pinto C, Jiménez-Hernández M, Munguía-Realpozo P, Ruiz-Argūelles A: Immunopathogenesis of vitiligo. Autoimmun Rev 2011, 10:762-765.
• [10]Fang D, Kute T, Setaluri V: Regulation of tyrosinase-related protein-2 (TYRP2) in human melanocytes: relationship to growth and morphology. Pigment Cell Res 2001, 14:132-139.
• [11]Ye Y, Chu JH, Wang H, Xv H, Chou GX, Leung AKM, Fong WF, Yu ZL: Involvement of p38 MAPK signaling pathway in the anti melanogenic effect of San-bai-tang, a Chinese herbal formula, in B16 cells. J Ethnopharmacol 2010, 132:533-535.
• [12]Park SH, Kim DS, Kim WG, Ryoo IJ, Lee DH, Huh CH, Youn SW, Yoo ID, Park KC: Terrein: a new melanogenesis inhibitor and its mechanism. Cell Mol Life Sci 2004, 61:2878-2885.
• [13]Hearing VJ, Jimenez M: Biochemical control of melanogenesis and melanosomal organization. J Investig Dermatol Symp Proc 1999, 4:24-28.
• [14]Kim YJ, Uyama H: Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future. Cell Mol Life Sci 2005, 62:1707-1723.
• [15]Yokoyama K, Yasumoto K, Suzuki H, Shibahara S: Cloning of the human DOPA chrome tautomerase/tyrosinase-related protein 2 gene and identification of two regulatory regions required for its pigment cell-specific expression. J Biol Chem 1994, 269:27080-27087.
• [16]Kobayashi T, Urabe K, Winder A, Jemenez-Cervantes C, Imokawa G, Brewington T, Solano F, Garcia-Borron JC, Hearing VJ: Tyrosinase related protein 1 (TRP-1) functions as a DHICA oxidase in melanin biosynthesis. EMBO J 1994, 13:5818-5825.
• [17]Levy C, Khaled M, Fisher DE: MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006, 12:406-414.
• [18]Tsang TF, Ye Y, Tai WC, Chou GX, Leung AK, Yu ZL, Hsiao WL: Inhibition of the p38 and PKA signaling pathways is associated with the anti melanogenic activity of Qian-wang-hong-bai-san, a Chinese herbal formula, in B16 cells. J Ethnopharmacol 2012, 141:622-628.
• [19]Hodgkinson CA, Moore KJ, Nakayama A, Teingrimsson E, Copeland NG, Jenkins NA, Arnheiter H: Mutations at the mouse microphthalmia locus are associated withdefects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 1993, 74:395-404.
• [20]Steingrimsson E, Moore KJ, Lamoreux ML, Ferre D’Amare AR, Burley SK, Zimring DC, Skow LC, Hodgkinson CA, Arnheiter H, Copeland NG, Jenkins NA: Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences. Nat Genet 1994, 8:256-263.
• [21]Busca R, Ballotti R: Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res 2000, 13(2):60-69.
• [22]Tachibana M: Cochlear melanocytes and MITF signaling. J Investig Dermatol Symp Proc 2001, 6:95-98.
• [23]Bentley NJ, Eisen T, Goding CR: Melanocyte specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol Cell Biol 1994, 14:7996-8006.
• [24]Aoki Y, Tanigawa T, Abe H, Fujiwara Y: Melanogenesis inhibition by an oolong tea extract in B16mouse melanoma cells and UV-induced skin pigmentation in brownish guinea pigs. Biosci Biotechnol Biochem 2007, 71:1879-1885.
• [25]Tomita Y, Maeda K, Tagami H: Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in post inflammatory pigmentation. Pigment Cell Res 1992, 5:357-361.
• [26]Shibahara S, Yasumoto KI, Amae S, Udono T, Watanabe KI, Saito H, Takeda K: Regulation of pigment cell-specific gene expression by MITF. Pigment Cell Res 2000, 13:98-102.
• [27]Costin GE, Hearing VJ: Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB J 2007, 21:976-994.
• [28]Zhu S, Wurdak H, Wang Y, Galkin A, Tao H, Li J, Lyssiotis CA, Yan F, Tu BP, Miraglia L, Walker J, Sun F, Orth A, Schultz PG, Wu X: A genomic screen identifies TYRO3 as MITF regulator in melanoma. Proc Nat Acad Sci USA 2009, 106:17025-17030.
• [29]Sensi M, Catani M, Castellano G, Nicolini G, Alciato F, Tragni G, De Santis G, Bersani I, Avanzi G, Tomassetti A, Canevari S, Anichini A: Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Investig Dermatol 2011, 131:2248-2257.
• [30]Wu H, Park HY: Protein kinase C-beta-mediated complex formation between tyrosinase and TRP-1. Biochem Biophys Res Commun 2003, 311:948-953.
• [31]Guibert S, Girardot M, Leveziel H, Julien R, Oulmouden A: Pheomelanin coat color dilution in French cattle breeds is not correlated with the TYR, TYRP1 and DCT transcription levels. Pigment Cell Res 2004, 17:337-345.